Total Payments
$2.7M
2024 Payments
$298,078
Companies
50
Transactions
2,176
Medicare Patients
2,565
Medicare Billing
$396,455
Payment Breakdown by Category
Other$2.1M (77.5%)
Travel$290,305 (10.8%)
Consulting$265,350 (9.9%)
Food & Beverage$36,310 (1.4%)
Research$6,783 (0.3%)
Education$2,773 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.1M | 651 | 77.3% |
| Travel and Lodging | $290,305 | 792 | 10.8% |
| Consulting Fee | $265,350 | 120 | 9.9% |
| Food and Beverage | $36,310 | 594 | 1.4% |
| Unspecified | $6,783 | 4 | 0.3% |
| Honoraria | $5,593 | 3 | 0.2% |
| Education | $2,773 | 12 | 0.1% |
Payments by Type
General
$2.7M
2,172 transactions
Research
$6,783
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $602,780 | 409 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $496,769 | 331 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $323,466 | 203 | $0 (2023) |
| Lilly USA, LLC | $312,105 | 338 | $0 (2024) |
| Genentech USA, Inc. | $261,655 | 197 | $0 (2024) |
| Merck Sharp & Dohme LLC | $189,313 | 177 | $0 (2024) |
| Amgen Inc. | $99,005 | 105 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $73,938 | 79 | $0 (2024) |
| Daiichi Sankyo Inc. | $73,637 | 67 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $38,462 | 46 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $298,078 | 229 | AstraZeneca Pharmaceuticals LP ($89,774) |
| 2023 | $446,281 | 316 | E.R. Squibb & Sons, L.L.C. ($83,627) |
| 2022 | $369,944 | 293 | AstraZeneca Pharmaceuticals LP ($97,539) |
| 2021 | $271,358 | 217 | AstraZeneca Pharmaceuticals LP ($106,890) |
| 2020 | $151,433 | 112 | AstraZeneca Pharmaceuticals LP ($48,932) |
| 2019 | $341,488 | 245 | AstraZeneca Pharmaceuticals LP ($75,403) |
| 2018 | $419,774 | 353 | Takeda Pharmaceuticals U.S.A., Inc. ($121,250) |
| 2017 | $379,886 | 411 | E.R. Squibb & Sons, L.L.C. ($109,286) |
All Payment Transactions
2,176 individual payment records from CMS Open Payments — Page 1 of 88
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,082.00 | General |
| Category: Oncology | ||||||
| 12/26/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | Cash or cash equivalent | $194.30 | General |
| 12/19/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $470.00 | General |
| 12/19/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | Cash or cash equivalent | $38.26 | General |
| 12/19/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | Cash or cash equivalent | $10.26 | General |
| 12/17/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Travel and Lodging | In-kind items and services | $803.42 | General |
| Category: Oncology | ||||||
| 12/17/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $47.62 | General |
| Category: Oncology | ||||||
| 12/16/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,988.00 | General |
| Category: Oncology | ||||||
| 12/12/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $3,150.00 | General |
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $650.47 | General |
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $532.61 | General |
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $121.83 | General |
| 12/10/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,880.00 | General |
| Category: ONCOLOGY | ||||||
| 12/09/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,447.00 | General |
| Category: Oncology | ||||||
| 12/05/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,640.00 | General |
| Category: Oncology | ||||||
| 12/03/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Travel and Lodging | Cash or cash equivalent | $1,297.06 | General |
| Category: Oncology | ||||||
| 12/03/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Travel and Lodging | Cash or cash equivalent | $1,017.49 | General |
| Category: Oncology | ||||||
| 12/03/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Travel and Lodging | Cash or cash equivalent | $213.83 | General |
| Category: Oncology | ||||||
| 12/03/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $121.78 | General |
| Category: Oncology | ||||||
| 11/25/2024 | Amgen Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,415.00 | General |
| 11/21/2024 | Amgen Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,900.00 | General |
| 11/20/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $122.95 | General |
| 11/19/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,560.00 | General |
| Category: Oncology | ||||||
| 11/19/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Travel and Lodging | Cash or cash equivalent | $681.68 | General |
| Category: Oncology | ||||||
| 11/19/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $78.53 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CT-P16 3.1 | Celltrion, Inc. | $5,513 | 2 |
| SASANLIMAB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,270 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 594 | 837 | $356,024 | $88,395 |
| 2022 | 11 | 635 | 915 | $387,010 | $92,407 |
| 2021 | 8 | 632 | 1,085 | $456,020 | $113,737 |
| 2020 | 9 | 704 | 1,205 | $403,925 | $101,917 |
Total Patients
2,565
Total Services
4,042
Medicare Billing
$396,455
Procedure Codes
35
All Medicare Procedures & Services
35 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 155 | 275 | $146,930 | $37,812 | 25.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 230 | 336 | $127,952 | $30,883 | 24.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 72 | 72 | $47,464 | $11,663 | 24.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 85 | 95 | $25,594 | $5,937 | 23.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 24 | 31 | $7,416 | $1,952 | 26.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 14 | 14 | $582.00 | $133.56 | 22.9% |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 2023 | 14 | 14 | $86.24 | $15.32 | 17.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 228 | 444 | $241,546 | $55,579 | 23.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 138 | 171 | $65,653 | $16,493 | 25.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 64 | 74 | $20,133 | $4,944 | 24.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 27 | 27 | $18,117 | $4,685 | 25.9% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 27 | 30 | $11,520 | $2,942 | 25.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 19 | 19 | $9,633 | $2,570 | 26.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 18 | 20 | $6,180 | $1,632 | 26.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 15 | 15 | $5,100 | $1,366 | 26.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 19 | 25 | $5,375 | $1,327 | 24.7% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 18 | 19 | $3,114 | $667.21 | 21.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 62 | 71 | $639.00 | $202.83 | 31.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 286 | 645 | $349,549 | $87,393 | 25.0% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 58 | 58 | $38,840 | $9,986 | 25.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 70 | 74 | $28,860 | $7,239 | 25.1% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 27 | 34 | $13,294 | $3,509 | 26.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 36 | 61 | $13,237 | $2,802 | 21.2% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 22 | 25 | $6,858 | $1,411 | 20.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 14 | 14 | $3,816 | $886.44 | 23.2% |
About Dr. Tarek Mekhail, M.D
Dr. Tarek Mekhail, M.D is a Hematology & Oncology healthcare provider based in Orlando, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1447214911.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Tarek Mekhail, M.D has received a total of $2.7M in payments from pharmaceutical and medical device companies, with $298,078 received in 2024. These payments were reported across 2,176 transactions from 50 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($2.1M).
As a Medicare-enrolled provider, Mekhail has provided services to 2,565 Medicare beneficiaries, totaling 4,042 services with total Medicare billing of $396,455. Data is available for 4 years (2020–2023), covering 35 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Orlando, FL
- Active Since 04/13/2006
- Last Updated 04/01/2013
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1447214911
Products in Payments
- OPDIVO (Biological) $490,255
- TAGRISSO (Drug) $345,109
- ALUNBRIG (Drug) $220,244
- TECENTRIQ (Biological) $176,396
- KEYTRUDA (Biological) $173,176
- IMFINZI (Biological) $148,167
- RETEVMO (Drug) $133,528
- LIBTAYO (Biological) $85,918
- LUMAKRAS (Drug) $68,040
- IMFINZI (Drug) $66,984
- CYRAMZA (Drug) $64,106
- EXKIVITY (Drug) $51,738
- Enhertu (Drug) $49,048
- Avastin (Biological) $40,170
- ALIMTA (Drug) $31,313
- KRAZATI (Drug) $30,324
- ENHERTU (Biological) $29,996
- GILOTRIF (Drug) $29,675
- MEKINIST (Drug) $19,415
- Abraxane (Drug) $14,169
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Orlando
Dr. Mark Socinski, Md, MD
Hematology & Oncology — Payments: $3.1M
Hematology & Oncology $3.1M
Dr. Daniel Landau, Md, MD
Hematology & Oncology — Payments: $2.0M
Hematology & Oncology $2.0M
Sajeve Thomas, Md, MD
Hematology & Oncology — Payments: $843,415
Hematology & Oncology $843,415
Rebecca Moroose, Md, MD
Hematology & Oncology — Payments: $790,811
Hematology & Oncology $790,811
Dr. Nikita Shah, Md, MD
Hematology & Oncology — Payments: $493,804
Hematology & Oncology $493,804
Dr. Guru Sonpavde, Md, MD
Hematology & Oncology — Payments: $425,119
Hematology & Oncology $425,119